Tulathromycin treatment does not affect bacterial dissemination or clearance of Brucella melitensis 16M following experimental infection of goats


Autoři: Paola M. Boggiatto aff001;  Steven C. Olsen aff001
Působiště autorů: Infectious Bacterial Diseases Research Unit, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, Iowa, United States of America aff001
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226242

Souhrn

Brucellosis in sheep and goats, a zoonotic disease primarily associated with Brucella melitensis infections, causes significant economic losses and public health concerns worldwide. Although control measures are effective, economic limitations and nomadic lifestyles may limit vaccination coverage, and test and removal policies may not be feasible. In this study, we evaluated the effects of therapy with a long acting antimicrobial tulathromycin on the pathogenesis of brucellosis. Thirty-five goats were randomly assigned for experimental infection with B. melitensis strain 16M while open or during mid-gestation. Approximately half of the animals in each group were then treated with tulathromycin and subsequently assessed for the development of humoral responses to infection, clinical presentation, and bacterial dissemination and colonization. All animals, regardless of treatment group were successfully challenged with B. melitensis 16M demonstrated by bacterial recovery from conjunctival swabs and development of positive antibody titers. In goats infected while open, no animals aborted and Brucella was recovered from only one animal in tulathromycin-treated and one animal from the untreated group. Tulathromycin treatment of pregnant goats did not prevent abortion nor did it reduce bacterial dissemination, colonization, or shedding. Our data suggests that treatment of goats in mid-gestation with tulathromycin at the labeled dose does not influence disease pathogenesis or tissue colonization after experimental B. melitensis challenge.

Klíčová slova:

Antibiotics – Antimicrobials – Goats – Intracellular pathogens – Respiratory infections – Vaccination and immunization – Brucella – Brucellosis


Zdroje

1. Olsen SC, Palmer MV. Advancement of knowledge of Brucella over the past 50 years. Vet Pathol. 2014;51(6):1076–89. doi: 10.1177/0300985814540545 24981716.

2. Bernues A, Manrique E, Maza MT. Economic evaluation of bovine brucellosis and tuberculosis eradication programmes in a mountain area of Spain. Prev Vet Med. 1997;30(2):137–49. doi: 10.1016/s0167-5877(96)01103-8 9234417.

3. Roth F, Zinsstag J, Orkhon D, Chimed-Ochir G, Hutton G, Cosivi O, et al. Human health benefits from livestock vaccination for brucellosis: case study. Bull World Health Organ. 2003;81(12):867–76. 14997239.

4. Lalsiamthara J, Lee JH. Development and trial of vaccines against Brucella. J Vet Sci. 2017;18(S1):281–90. doi: 10.4142/jvs.2017.18.S1.281 28859268.

5. Berman DT, Irwin MR, Beach BA. The effect of penicillin on cows infected with Brucella abortus. Cornell Vet. 1946;36(4):311–3. 20289305.

6. Dumaresq JA. Effect of sulfanilamide on Brucella abortus infection in guinea pigs and cows. Australian Veterinary Journal. 1940;16:102–7.

7. Schuhard VT, Rich G.C., Beal G.A. Sulfadiazine therapy in bovine brucellosis. J Bact. 1945;50:127–31.

8. Fensterbank R. [Oxytetracycline treatment of cows with long-standing brucellosis]. Ann Rech Vet. 1976;7(3):231–40. 829211.

9. Milward FW, Nicoletti P, Hoffmann E. Effectiveness of various therapeutic regimens for bovine brucellosis. Am J Vet Res. 1984;45(9):1825–8. 6208830.

10. Nicoletti P, Lenk RP, Popescu MC, Swenson CE. Efficacy of various treatment regimens, using liposomal streptomycin in cows with brucellosis. Am J Vet Res. 1989;50(7):1004–7. 2505648.

11. Nicoletti P, Milward FW, Hoffmann E, Altvater L. Efficacy of long-acting oxytetracycline alone or combined with streptomycin in the treatment of bovine brucellosis. J Am Vet Med Assoc. 1985;187(5):493–5. 3932272.

12. Dieste-Perez L, Frankena K, Blasco JM, Munoz PM, de Jong MC. Efficacy of antibiotic treatment and test-based culling strategies for eradicating brucellosis in commercial swine herds. Prev Vet Med. 2016;126:105–10. doi: 10.1016/j.prevetmed.2016.01.033 26899897.

13. Letavic MA, Bronk BS, Bertsche CD, Casavant JM, Cheng H, Daniel KL, et al. Synthesis and activity of a novel class of tribasic macrocyclic antibiotics: the triamilides. Bioorg Med Chem Lett. 2002;12(19):2771–4. doi: 10.1016/s0960-894x(02)00526-7 12217373.

14. Villarino N, Brown SA, Martin-Jimenez T. The role of the macrolide tulathromycin in veterinary medicine. Vet J. 2013;198(2):352–7. doi: 10.1016/j.tvjl.2013.07.032 24268476.

15. Zoetis. Draxxin (tulathromycin) Injectable Solution—Package Insert. In: Zoetis, editor. 2014.

16. Young G, Smith GW, Leavens TL, Wetzlich SE, Baynes RE, Mason SE, et al. Pharmacokinetics of tulathromycin following subcutaneous administration in meat goats. Res Vet Sci. 2011;90(3):477–9. doi: 10.1016/j.rvsc.2010.06.025 20638089.

17. Clothier KA, Leavens T, Griffith RW, Wetzlich SE, Baynes RE, Riviere JE, et al. Tulathromycin assay validation and tissue residues after single and multiple subcutaneous injections in domestic goats (Capra aegagrus hircus). J Vet Pharmacol Ther. 2012;35(2):113–20. doi: 10.1111/j.1365-2885.2011.01300.x 21762403.

18. Dieste-Perez L, Fraile L, de Miguel MJ, Barberan M, Blasco JM, Munoz PM. Studies on a suitable antibiotic therapy for treating swine brucellosis. J Vet Pharmacol Ther. 2015;38(4):357–64. doi: 10.1111/jvp.12189 25413993

19. Kuzdas CD, Morse EV. A selective medium for the isolation of brucellae from contaminated materials. J Bacteriol. 1953;66(4):502–4. 13096514.

20. Alton GG, Jones, L.M., Angus, R.D., Verger, J.M.. Techniques for the brucellosis laboratory. Institut National de la Recherche Agronomique. 1988;Paris, France.

21. Lee IK, Olsen SC, Bolin CA. Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model. Can J Vet Res. 2001;65(4):223–8. 11768128.

22. Stoffregen WC, Johnson CS, Olsen SC. Immunogenicity and safety of a natural rough mutant of Brucella suis as a vaccine for swine. Res Vet Sci. 2013;95(2):451–8. Epub 2013/05/11. doi: 10.1016/j.rvsc.2013.04.014 23659743.

23. Blasco JM. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med. 1997;31(3–4):275–83. doi: 10.1016/s0167-5877(96)01110-5 9234451.

24. Marin CM, Jimenez de Bagues MP, Barberan M, Blasco JM. Efficacy of long-acting oxytetracycline alone or in combination with streptomycin for treatment of Brucella ovis infection of rams. Am J Vet Res. 1989;50(4):560–3. 2712423.

25. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents. 2005;26(2):101–5. Epub 2005/07/26. doi: 10.1016/j.ijantimicag.2005.06.001 16039098.

26. Garcia-Rodriguez JA, Munoz Bellido JL, Fresnadillo MJ, Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother. 1993;37(4):911–3. Epub 1993/04/01. doi: 10.1128/aac.37.4.911 8494391.


Článek vyšel v časopise

PLOS One


2019 Číslo 12